Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832179 · ClinicalTrials.gov registry record · Phase 4
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
A Phase 4 study, sponsored by Bay Area Retina Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT03832179: Completed Phase 4 study, sponsored by Bay Area Retina Associates.
NCT03832179 is a Phase 4 study that has completed, run by Bay Area Retina Associates. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832179, a Phase 4 study, has completed, sponsored by Bay Area Retina Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
Primary Outcome
Central foveal thickness will be measured in microns by spectral domain optical coherence tomography (Heidelberg) and compared to baseline at post-operative week 1, postoperative month 1, postoperative month 2, and postoperative month 3 for both anti-vascular endothelial growth factor and Ozurdex groups
Interventions
- DRUG Bevacizumab
- DRUG Aflibercept
- DRUG Ranibizumab
- DRUG Ozurdex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 4 |
What the finished NCT03832179 record still lists
NCT03832179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03832179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03832179 about?
NCT03832179 is a clinical study titled "Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification". The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
What is the current status of trial NCT03832179?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2018-11-15. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT03832179?
The interventions under investigation include: Bevacizumab (DRUG), Aflibercept (DRUG), Ranibizumab (DRUG), Ozurdex (DRUG).
Who is sponsoring clinical trial NCT03832179?
This trial is sponsored by Bay Area Retina Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03832179's enrollment target sits among peer trials
16 1869th of 2000 higher than 121 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI